ATRA: Atara Biotherapeutics Inc

ATRA新闻

• 12:08 Atara Biotherapeutics' Partner Pierre Fabre Pharmaceuticals Receives FDA Acceptance To Refile Biologics License Application For Tabelecleucel To Treat Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
• 12:09 Atara Biotherapeutics' Pierre Fabre Pharmaceuticals Partner Refiles Tabelecleucel Biologics License Application With FDA
• 12:09 Atara Biotherapeutics 的合作伙伴 Pierre Fabre Pharmaceuticals 重新向 FDA 提交 tabelecleucel 生物制品许可申请
• 10:30 HQL: The Rally That Makes Growth Harder (Rating Downgrade) (NYSE:HQL)
• 18:12 Biotech Stocks Surge As UniQure 'Nail-Biting Journey' Comes To An End
• 13:06 Uniqure Catapults 60% On A Gene Therapy Shock From The FDA
• 14:37 ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
• 17:58 Morning News Wrap-Up, 5/7/26: Today’s Biggest Stock Market Stories! - TipRanks.com
• 12:13 Atara schedules FDA meeting on tabelecleucel license application
• 13:14 Pierre Fabre requests FDA meeting on tabelecleucel approval
• 13:05 Atara extends $9M milestone payment deadline to 2028
• 02:38 Atara Bio董事黄杰姆出售价值48.9万美元股份
• 02:37 Atara Bio director Huang James sells $489k in shares
• 21:30 美国股市上涨；截至收盘道琼斯工业平均指数上涨0.17%
• 21:30 U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.17%
• 18:26 FDA出人意料地拒绝Atara的tabelecleucel申请